Rocket Lab (RKLB) Stock: Why Analysts See 33% Upside Despite Recent Dip

Key Takeaways

• Wall Street analysts set an average target of $89.36 for RKLB, suggesting approximately 33% appreciation potential
• The company secured a $190M Pentagon contract for hypersonic testing missions, elevating its order book beyond $2 billion
• Clear Street launched coverage with a Buy recommendation and $88 target price
• Neutron rocket major components completed and ready for integration, targeting Q4 2026 liftoff
• Company insiders divested more than $136M in shares over the past three months, sparking dilution questions

Rocket Lab (RKLB) has retreated roughly 6.5% in recent trading sessions, currently sitting at $67.23. Yet the Street remains optimistic about its trajectory.

Rocket Lab USA, Inc., RKLB

The consensus price target among analysts stands at $89.36 — representing roughly 33% potential upside from present levels. Nine analysts maintain Buy recommendations, while four advise holding.

The recent decline follows a series of company milestones. Broader market pressure on aerospace and defense names, driven by Middle Eastern geopolitical uncertainty, has temporarily weighed on RKLB shares.

The company’s most significant recent announcement involves a $190 million Department of Defense award. This agreement encompasses as many as 20 HASTE hypersonic test missions — marking the largest launch services agreement in the company’s history. CEO Sir Peter Beck described it as a “proud moment” for the organization.

This Pentagon contract elevated Rocket Lab’s total order backlog above the $2 billion threshold. This represents substantial locked-in future revenue visibility.

The company also successfully executed its 84th Electron mission — marking the 8th deployment for Synspective. This accomplishment underscores Rocket Lab’s consistent launch tempo and durable client partnerships in the constellation market.

Neutron Development Progresses Toward Maiden Flight

The Neutron program represents the company’s most ambitious long-term initiative. This 43-meter partially reusable launch vehicle targets satellite constellation deployments and cargo transport missions. The system positions Rocket Lab in direct rivalry with SpaceX’s Falcon 9 platform.

Critical systems — including the “Hungry Hippo” payload fairing and main thrust assembly — have now completed production and await final integration. The inaugural launch window remains set for Q4 2026, following a modest manufacturing-related schedule adjustment.

Clear Street’s Gregory Pendy recently launched coverage with a Buy thesis and $88 valuation, highlighting the company’s vertically integrated manufacturing as a strategic differentiator. His model projects Electron mission frequency scaling to approximately 52 annual launches by decade’s end.

Cantor Fitzgerald’s Andres Sheppard reaffirmed his Buy stance with an $85 objective, identifying the inaugural Neutron mission as the most significant near-term catalyst for share performance.

Executive Stock Sales Draw Attention

Not all signals point upward. Company executives have been reducing positions. CFO Adam Spice disposed of 62,744 shares at $69.59 in early March, trimming his holdings by 4.61%. Director Frank Klein subsequently sold 36,768 shares at $71.95.

Cumulatively, corporate insiders have liquidated over 1.81 million shares valued at approximately $136.5 million during the previous 90-day period. This activity has drawn scrutiny from shareholders monitoring potential dilution dynamics, particularly following a recent equity offering.

Institutional investor activity tells a contrasting story. Swiss Life Asset Management expanded its position by 480.9%, acquiring 48,369 additional shares. AQR Capital increased its stake by 114%. Institutional ownership currently represents 71.78% of outstanding shares.

Morgan Stanley elevated RKLB from Equal Weight to Overweight this past January, raising its target to $105. Needham maintains a Buy rating with a $95 objective. Zacks Research shifted to Hold status in February.

RKLB’s 52-week trading band extends from $14.71 to $99.58. The stock’s 50-day moving average currently sits at $76.31.

The post Rocket Lab (RKLB) Stock: Why Analysts See 33% Upside Despite Recent Dip appeared first on Blockonomi.